Tafasitamab (Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix) |
رقم الكتالوجGC65433 |
Tafasitamab (XmAb5574) هو جسم مضاد أحادي النسيلة معدّل بواسطة البشر والذي يرتبط بمستضد سطح الخلية B البشرية CD19
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1422527-84-1
Sample solution is provided at 25 µL, 10mM.
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].
Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].
Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1].
[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.
[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *